5-methoxytryptamine

5-Methoxytryptamine (5-MT): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Identifiers

5-Methoxytryptamine (abbreviated 5-MT, also rendered as 5-MeO-T or 5-OMe-T), also known by the synonyms serotonin methyl ether, O-methylserotonin, and under the pharmacological trade name mexamine, is a tryptamine derivative closely related to the neurotransmitters serotonin and melatonin. Its CAS registry number is 608-07-1, and its chemical structure is characterized by a tryptamine backbone featuring a methoxy (–OCH₃) group at the 5-position of the indole ring.

5-MT is a substituted tryptamine and a derivative of serotonin (5-hydroxytryptamine) and a direct precursor of melatonin (N-acetyl-5-methoxytryptamine). The predicted log P of 5-MT is 0.5 to 1.41, reflecting moderate lipophilicity. 5-MT is closely related to other 5-methoxylated tryptamines such as 5-MeO-NMT, 5-MeO-DMT, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-MiPT, 5-MeO-DALT, and 5-MeO-AMT.

Position in the Indoleamine Metabolic Pathway

The broader indoleamine pathway begins with tryptophan, which is converted to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase; decarboxylation then yields serotonin (5-hydroxytryptamine, 5-HT), which is further transformed to melatonin (N-acetyl-5-methoxytryptamine). 5-MT sits at an intermediate position within this pathway: it can be formed by O-methylation of serotonin mediated by hydroxyindole O-methyltransferase (HIOMT), or alternatively by N-deacetylation of melatonin. It is also a precursor of 5-MeO-DMT in some species.

Natural Sources and Occurrence

5-MT has been shown to occur naturally in the pineal gland of the brain, where it occupies a structural and biochemical position between serotonin and melatonin. In the pineal gland and non-mammalian retina, deacetylation of melatonin to 5-methoxytryptamine (5-MT) plays a recognized role. This pathway is quantitatively prevalent in dinoflagellates, in which 5-MT induces cyst formation and is further converted to 5-methoxyindole-3-acetic acid, an end product released to the water.

In plants, under stress conditions or during senescence when serotonin accumulates to high levels, it can be converted to 5-methoxytryptamine by the enzymes ASMT/COMT and subsequently to melatonin by SNAT, causing the final step of melatonin biosynthesis to occur in chloroplasts. In yeasts such as Saccharomyces cerevisiae, the detection of 5-methoxytryptamine as an intermediate suggests that melatonin may be synthesized directly from this compound.

Common Forms and Preparations

The chemical synthesis of 5-MT has been described and is primarily available as a pure research chemical, typically as its hydrochloride salt. Melatonin can be prepared from a reaction mixture involving 5-methoxytryptamine hydrochloride, pyridine, and acetic anhydride, which illustrates its direct utility as a synthetic precursor. 5-MT was encountered online as a reported designer drug by 2023, though it occupies a very different profile from most designer substances due to its endogenous nature and complex pharmacology.

2. Historical and Pharmacological Research Context

Early Scientific Description

5-MT was first described in the scientific literature by at least 1925. Subsequently, it was studied in the 1950s following the discovery of serotonin's chemical structure in the late 1940s and early 1950s. Early interest grew from the recognition that 5-MT was a direct O-methyl analogue of serotonin, raising questions about its endogenous role and pharmacological properties.

Soviet Radioprotection Research (Mexamine Program)

The drug was extensively studied under the name mexamine (or meksamina) as a radioprotective agent by the Soviet Union from the 1960s and thereafter. This represented the most sustained organized research effort specifically focused on 5-MT as an administered compound. Research in this program included studies on antihypoxic properties and toxicity of mexamine. The therapeutic index for the radioprotective effect of mexamine (5-methoxytryptamine) injected intraperitoneally to mice 5 min before high-dose irradiation was evaluated comparatively with other radioprotectors, including serotonin, tryptamine, cystamine, and catecholamines; researchers noted a decrease in the therapeutic index of mexamine and cystamine in larger animals.

The decrease in the radioprotective effect and the therapeutic index of mexamine in experiments with dogs may be caused by their lower sensitivity to the acute hypoxia induced by mexamine, because of a lower gradient in oxygen tension between tissue cells and blood capillaries under acute hypoxia in large animals compared with small animals.

Shulgin and the TiHKAL Monograph

5-MT was briefly described by Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) in 1997. Shulgin's coverage was limited, reflecting the fact that 5-MT is inactive in humans, at least orally, likely due to rapid metabolism by monoamine oxidase (MAO).

Relationship to Designer Drug Precursors

5-Methoxytryptamine (mexamine) is a precursor for the synthetic compounds "Foxy" (5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT) and "Moxy" (5-methoxy-N-methyl-N-isopropyltryptamine, 5-MeO-MiPT); "Foxy" is a controlled substance in the USA and EU countries.

3. Biochemistry: Active Compound and Biosynthetic Pathways

Biosynthesis in Mammals

5-MT can be formed by O-methylation of serotonin mediated by hydroxyindole O-methyltransferase (HIOMT), or by N-deacetylation of melatonin. Both routes place it as a metabolic intermediate in the pineal indoleamine pathway. It is naturally found in the human body in low concentrations, biosynthesized through the deacetylation of melatonin in the pineal gland.

Metabolism and Catabolism

5-MT is metabolized by deamination by monoamine oxidase (MAO), specifically monoamine oxidase A (MAO-A) and to a much lesser extent by monoamine oxidase B (MAO-B). This rapid first-pass metabolism by MAO-A is considered the primary reason for the compound's lack of oral activity in humans. The levels and effects of 5-MT are dramatically potentiated by monoamine oxidase inhibitors (MAOIs) in animals.

In animal studies, the behavioral effects of centrally administered 5-MT in rats are markedly enhanced by MAOIs, including by the dual MAO-A and MAO-B inhibitor iproniazid as well as by clorgyline and selegiline; the non-selective inhibitor tranylcypromine has also been frequently used to potentiate the effects of 5-MT. Similarly, pineal gland levels of endogenous 5-MT are dramatically elevated by the MAO-A inhibitor clorgyline and by the dual MAO-A and MAO-B inhibitor pargyline in hamsters, and plasma levels of exogenous 5-MT are greatly elevated by these MAOIs; selegiline was ineffective in elevating brain or plasma 5-MT levels in hamsters. This pattern of selective sensitivity to MAO-A (but not MAO-B) inhibition is consistent with 5-MT's primary metabolic route.

4. Mechanisms of Action

Serotonin Receptor Agonism: Broad Profile

5-MT is a highly potent and non-selective serotonin receptor agonist and shows psychedelic-like effects in animals. 5-MT acts primarily as a non-selective agonist at multiple serotonin (5-HT) receptor subtypes, exhibiting high affinity for several G protein-coupled receptors within the 5-HT family. Peer-reviewed receptor binding data places its activity across the following subtypes:

• 5-HT1A: Through potent agonism at presynaptic 5-HT1A autoreceptors, 5-MT modulates serotonin release by providing negative feedback on serotonergic neurons in regions such as the hypothalamus.
• 5-HT2A: The psychedelic-like effects of 5-MT, including induction of the head-twitch response in rodents, are primarily mediated via 5-HT2A receptor activation, a hallmark of serotonergic hallucinogen pharmacology.
• 5-HT4, 5-HT6, 5-HT7: The 5-HT4, 5-HT6, and 5-HT7 receptors couple to Gs proteins, enhancing adenylyl cyclase activity and elevating cAMP concentrations.
• 5-HT6 (high-affinity binding): Agents that bind at human 5-HT6 receptors with Ki values < 50 nM include 5-methoxytryptamine alongside bromocriptine, octoclothepin, and the neuroleptics clozapine, olanzapine, loxapine, chlorpromazine, and fluphenazine.

Signal Transduction

Serotonin receptors signal through multiple mechanisms: 5-HT1 and 5-HT5 receptor activation promotes inhibition of adenylate cyclase; 5-HT4, 5-HT6, and 5-HT7 activation stimulates adenylate cyclase; and 5-HT2 activation stimulates phospholipase C; 5-HT3 is an ionotropic ligand-gated Na⁺/K⁺ channel. Given that 5-MT binds across multiple families, its net downstream effects in any given tissue are a product of the local receptor density and the coupling efficiency at each subtype.

Blood–Brain Barrier Penetration

5-MT is able to cross the blood–brain barrier and enter the central nervous system with peripheral administration in animals. However, it has also been reported that 5-MT shows strong peripheral selectivity in animals comparable to serotonin and bufotenin, and that its capacity to exert central effects is limited. This apparently contradictory evidence may reflect dose- and species-dependence. It was hypothesized that reduced blood–brain barrier permeability with drugs like 5-MT might be involved in certain behavioral findings.

Comparison with Related 5-Methoxytryptamines

5-HT1A plays a role in the behavioural effects of tryptamine hallucinogens, particularly 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); although 5-HT1A is a validated therapeutic target, little is known about how psychedelics engage 5-HT1A and which effects are mediated by this receptor. Researchers have mapped the molecular underpinnings of 5-methoxytryptamine pharmacology at 5-HT1A through cryogenic electron microscopy (cryo-EM) structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis, and mouse behaviour.

5. Scientific Evidence by Area of Use

5.1 Radioprotection

The most extensively investigated application of 5-MT (as mexamine) was radioprotection. Antioxidants are prospective radioprotectors because of their ability to scavenge radiation-induced reactive oxygen species (ROS); the hematopoietic system is widely studied in radiation research because of its high radiosensitivity. One study described the beneficial effects of a 5-methoxytryptamine-α-lipoic acid conjugate (MLA) against radiation-induced hematopoietic injury. MLA administration significantly enhanced the survival rate of mice after 7.2 Gy total body irradiation; MLA markedly increased the numbers and clonogenic potential of hematopoietic cells while decreasing DNA damage, as determined by flow cytometric analysis of histone H2AX phosphorylation; MLA also decreased levels of ROS in hematopoietic cells by inhibiting NOX4 expression, demonstrating that MLA prevents radiation-induced hematopoietic syndrome.

In experiments on mice, studies examined different substituents in the 4th position of the indole ring of 5-methoxytryptamines on toxicity and radioprotective efficiency. Adding an amino group to the mexamine molecule increased preparation toxicity; the nitro group somewhat diminished toxic properties; a 5-MOT derivative with a nitro group possessed the strongest radioprotective action, and the radioprotective efficiency of these compounds persisted for 1–2 hours.

One study investigated the combined effect of 5-methoxytryptamine (mexamine) and high-concentration calcium and potassium ion solutions on the depilatory action of X-rays in young C57Bl mice; whole-body protection of the coat was induced with an intraperitoneal injection of mexamine. An intraperitoneal injection of mexamine in a dose of 5 mg/kg body weight 5 min before irradiation was used in this model.

Evidence strength: All radioprotection studies are preclinical, conducted in rodents or larger animals (dogs, monkeys) under Soviet-era research programs. No human clinical trials on the radioprotective use of 5-MT itself have been identified in the indexed literature. Evidence is entirely animal/in-vitro and is of historical interest; it does not establish clinical efficacy or safety in humans.

5.2 Neurodevelopmental Research

Previous studies with tissue culture models of neuronal development showed that the development of serotonin neurons is dependent, at least in part, on the stimulation of high-affinity serotonin receptors; one receptor inhibits neuronal outgrowth while the other promotes it. To test this in a whole-animal model, pregnant Sprague-Dawley rats were treated from gestational day 12 until birth with 0.1, 1.0, or 3.0 mg/kg 5-methoxytryptamine (5-MT); pups were assessed for serotonin outgrowth by selective synaptosomal uptake of [³H]serotonin at postnatal days 1, 15, and 30, and were tested behaviorally for the neonatal serotonin syndrome, spontaneous alternation, open field activity, and lick suppression.

The highest dose caused behavioral alterations that had abated by 30 days, while the intermediate dose (1.0 mg/kg) showed behavioral changes throughout; at the lowest dose (0.1 mg/kg), changes in uptake appeared only at day 1 and behavioral changes only at later timepoints, principally at day 30. This suggests that serotonin plays a role in regulating the development of the neurons which produce it, and may also play a role in neurochemical imprinting—that changes in adult behavior may be due to changes in neurochemistry during development, even though that neurochemistry may have been corrected by the time the animal becomes an adult.

In an earlier study, 5-methoxytryptamine (5-MT) was administered to pregnant Sprague-Dawley rats from day 12 of gestation until birth; birth weights of 5-MT-exposed neonates were approximately 20% less than saline-injected controls. 5-MT neonates showed a significant reduction of high-affinity [³H]5-HT uptake in the brainstem at all three postnatal timepoints; behavioral measurements revealed deficits in general activity, spontaneous alternation, and passive avoidance.

Evidence strength: All neurodevelopmental evidence comes from animal studies (rats), using injected doses that are not relevant to any current human use. These findings are important for understanding the role of serotonin receptor stimulation in brain development but do not constitute human evidence and are not applicable to dietary supplementation contexts.

5.3 Gastrointestinal Motility

5-HT4 receptor (5-HT4R) agonists promote gastrointestinal motility and attenuate visceral pain. 5-MT has been employed as a pharmacological tool to characterize 5-HT4 receptor activity in the gastrointestinal tract. Research characterized the contractile response induced by 5-methoxytryptamine in rat stomach fundus strips. 5-methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization have been used as a discriminative pharmacological tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum.

In enteric nervous system research, 5-methoxytryptamine (5-MeOT; 50 μM) was used as a 5-HT4 agonist in patch-clamp studies on neurons of the mouse enteric nervous system. Activation of 5-HT4 by unilateral microinjection of 5-methoxytryptamine into the nucleus tractus solitarius (NTS) in anesthetized rats had no effect on baseline blood pressure, heart rate, and inspiratory drive (phrenic nerve discharge), but attenuated the bradycardia and decreased the inhibitory action on inspiratory drive caused by activation of the cardiopulmonary reflex; this effect was prevented by pretreatment with the 5-HT4 antagonists RS-23597 or RS-39604.

Evidence strength: Entirely preclinical (in-vitro tissue preparations and animal models). 5-MT has been used here as a research tool to characterize receptor pharmacology, not as a candidate therapeutic. No human studies exist in this domain.

5.4 Behavioral Pharmacology and Psychedelic-like Effects (Animal Models)

5-MT is a highly potent and non-selective serotonin receptor agonist and shows psychedelic-like effects in animals. The primary behavioral proxy for psychedelic activity in rodents—the head-twitch response (HTR)—has been studied with mixed results for 5-MT. In a couple of more recent studies, 5-MT failed to produce the HTR, instead inducing only serotonin 5-HT1A receptor-mediated hypothermia and hypolocomotion; in one of these studies, the ED50 of 5-MT in producing the HTR was greater than 30 mg/kg, whereas the ED50 of 5-MeO-DMT was 0.33 mg/kg, representing at least a 91-fold difference. Conversely, 5-MT was 2.8-fold more potent than 5-MeO-DMT in producing hypolocomotion and only slightly less potent in producing hypothermia.

Besides these effects, 5-MT produces a "hyperactivity syndrome" in rodents. 5-MeO-T exhibited psychotomimetic potential similar to LSD through high affinity with presynaptic 5-HT receptors (De Montigny and Aghajanian, 1977).

Evidence strength: All behavioral data are from rodent models. There are no human clinical or observational studies examining the psychoactive effects of 5-MT itself, and it is currently considered orally inactive in humans.

5.5 Antioxidant and Neuroprotective Potential

Beyond its receptor activity, 5-methoxytryptamine has been noted in preliminary research as having demonstrated potential as an antioxidant, a radiation-protective agent, and a neuroprotective agent. These properties are structurally plausible given its close chemical relationship to melatonin, which is extensively documented as a potent antioxidant. Melatonin (N-acetyl-5-methoxytryptamine) is a potent antioxidant of growing interest; beyond circadian regulation, it is a pleiotropic hormone with antioxidant and anti-inflammatory properties, capable of crossing biological barriers and accumulating in mitochondria. Whether 5-MT itself shares meaningful antioxidant activity in vivo, independent of its conversion to or from melatonin, has not been established in human studies.

Evidence strength: Preliminary; structural inference from the melatonin literature and limited preclinical data. No dedicated human clinical trials on 5-MT's antioxidant or neuroprotective properties have been identified.

6. Body Systems and Health Areas Associated with 5-MT

Central Nervous System

The 5-HT pathways in the brain are important targets for drug development in the area of CNS disorders; serotonin and its receptors are involved in a wide variety of actions including cognition, mood, anxiety, attention, appetite, cardiovascular function, vasoconstriction, and sleep. Because 5-MT is a potent, broad-spectrum serotonin receptor agonist, it interacts with CNS pathways governing all of these functions in animal models—but its practical access to CNS targets in humans after oral administration is severely limited by MAO-A catabolism.

Pineal Gland and Circadian Biology

Melatonin (N-acetyl-5-methoxytryptamine) is now well recognized as the most influential hormone in the physiological regulation of circadian rhythm; it is synthesized from the precursor amino acid tryptophan and secreted into the bloodstream of both humans and mammals via the pineal gland. As a direct metabolite of both serotonin and melatonin, 5-MT is functionally embedded in the circadian biology of the pineal gland, even if its specific independent physiological role in sleep–wake regulation is not well characterized at the human level.

Hematopoietic System

The hematopoietic system is widely studied in radiation research because of its high radiosensitivity. As described above, mexamine was studied for its capacity to protect hematopoietic stem cells from ionizing radiation in animal models.

Gastrointestinal System

Among the mediators involved in the regulation of the migrating motor complex (MMC) of the gastrointestinal tract, an increasing number of reports point out that 5-hydroxytryptamine (5-HT) has a pivotal role; this pattern is disturbed in patients suffering from several gastrointestinal disorders. 5-MT, through its 5-HT4 agonism, has been used as a pharmacological research tool to probe gastrointestinal serotonergic signaling.

Cardiovascular System

Serotonin and its receptors exert direct postjunctional (on vascular smooth muscle and endothelium) or indirect prejunctional (on autonomic and sensory perivascular nerves) effects relevant to blood pressure regulation. In radioprotection models, mexamine's mechanism was partly linked to the acute induction of hypoxia in radiosensitive tissues, implicating cardiovascular effects as a component of its protective action.

7. Pharmacokinetics and Dosage

Oral Bioavailability

5-MT is said to be orally inactive in humans, presumably due to rapid metabolism by monoamine oxidase (MAO). This is the defining pharmacokinetic limitation of 5-MT as a potential orally ingested supplement or drug. 5-MeO-AMT is orally active in humans, in contrast to 5-MT, and could be thought of as a sort of orally active form of 5-MT.

Peripheral Administration in Animal Models

5-Methoxytryptamine demonstrates rapid absorption following parenteral administration in animal models, with peak plasma concentrations achieved within 5 minutes after intraperitoneal injection of 50 mg/kg in rats (5.3 μg/mL).

Radioprotection Dosage (Animal Data Only)

In radioprotection studies, intraperitoneal injection of mexamine at a dose of 5 mg/kg body weight, administered 5 minutes before irradiation, was used as the "whole body coat-protective dose" in C57Bl mice. These doses are from animal experiments and have no direct translation to human use.

Neurodevelopmental Dosage (Animal Data Only)

In prenatal neurodevelopmental studies, pregnant Sprague-Dawley rats were treated from gestational day 12 until birth with 0.1, 1.0, or 3.0 mg/kg 5-methoxytryptamine (5-MT). These doses illustrate the dose-response relationships studied in animal models and are not relevant to human supplementation.

In-Vitro Pharmacological Tool Concentrations

In enteric nervous system electrophysiology studies, 5-methoxytryptamine was applied at 50 μM as a 5-HT4 agonist in patch-clamp neuron experiments. Such concentrations are used to characterize receptor pharmacology in isolated tissue and are not translatable to whole-organism dosing.

8. Safety, Toxicology, and Drug Interactions

Oral Inactivity and MAO Dependence

5-MT is a highly potent and non-selective serotonin receptor agonist and shows psychedelic-like effects in animals; however, it is inactive in humans, at least orally, likely due to rapid metabolism by monoamine oxidase (MAO). This means that the compound's risk profile in a healthy human without MAOI co-administration is substantially mitigated compared to its pharmacological potency in vitro or in animals. However, this changes dramatically in the presence of MAOIs.

MAOI Interactions and Serotonergic Toxicity Risk

The levels and effects of 5-MT are dramatically potentiated by monoamine oxidase inhibitors (MAOIs) in animals. The general principle that combines MAOIs with serotonergic tryptamines carries significant risks: the combination of monoamine oxidase inhibitors (MAOIs) with tryptamine agonists can present similar dangers to their combination with serotonin precursors; the case of combination of MAOIs with tryptamine agonists (commonly known as ayahuasca) can present similar dangers as their combination with serotonin precursors.

Overstimulation of primarily the serotonin 5-HT2A receptors appears to contribute substantially to serotonin syndrome, while the serotonin 5-HT1A receptor seems to play little direct role; however, 5-HT1A may still contribute through a pharmacodynamic interaction in which increased synaptic concentrations of a serotonin agonist saturate all receptor subtypes. Given 5-MT's potent binding at both 5-HT1A and 5-HT2A, and its broad non-selective receptor profile, co-administration with MAOIs would be expected to significantly increase serotonergic load.

Radioprotection Toxicity (Preclinical)

In mouse studies examining structural analogues of mexamine, administration of an amino-group to the mexamine molecule increased preparation toxicity. Researchers presented hypotheses explaining the decrease in the therapeutic index of 5-methoxytryptamine (mexamine) in larger animals.

Regulatory Status

5-MT is not a controlled substance in Canada as of 2025. There is no identified scheduling of 5-MT itself under the U.S. Controlled Substances Act or EU frameworks, though regulatory status varies by jurisdiction and may differ from derivatives such as 5-MeO-DiPT, which are controlled.

Absence of Human Clinical Safety Data

There are no identified peer-reviewed human clinical trials, systematic reviews, or pharmacovigilance databases specifically documenting the safety profile of 5-MT administered to humans. All toxicological data derives from animal studies (primarily rodents and, in the Soviet radioprotection literature, dogs and primates). The compound's behavior in humans, the dose–response profile, long-term safety, and potential adverse effects in human populations remain entirely uncharacterized in the clinical literature.

9. Research Tool Applications

5-MT's primary documented contemporary use is as a research reagent in receptor pharmacology. Its action as a non-selective agonist at multiple serotonin receptor subtypes makes it a valuable pharmacological tool for receptor characterization studies. Researchers have mapped the molecular underpinnings of 5-methoxytryptamine pharmacology through cryo-EM structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis, and mouse behaviour in order to understand how the 5-methoxytryptamine scaffold interacts with therapeutically relevant targets. Structure–activity relationship analyses of 5-methoxytryptamines at both 5-HT1A and 5-HT2A have enabled the characterization of selective probes; the anxiolytic-like and antidepressant-like effects of these probes in preclinical models emphasize their utility in elucidating 5-HT1A-mediated effects and potentially facilitating exploration of therapeutic applications.

References

• Wikipedia – 5-Methoxytryptamine
• PMC / Nature – Structural pharmacology and therapeutic potential of 5-methoxytryptamines (2024)
• Nature – Structural pharmacology and therapeutic potential of 5-methoxytryptamines
• PMC / Journal of Neurochemistry – The clinical pharmacology and potential therapeutic applications of 5-MeO-DMT (Reckweg et al., 2022)
• PubMed – The clinical pharmacology and potential therapeutic applications of 5-MeO-DMT
• PMC – 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology
• PMC / IJMS – The Protective Effects of 5-Methoxytryptamine-α-lipoic Acid on Ionizing Radiation-Induced Hematopoietic Injury (Li et al., 2016)
• Journal of Radiation Research – Comparative efficacy and the window of radioprotection for adrenergic and serotoninergic agents and aminothiols (2015)
• PubMed – Radioprotective effectiveness and toxicity of 4,5-disubstituted tryptamines
• PubMed – Study of the radioprotective effect of 5-methoxytryptamine on haemopoietic stem cells
• PubMed – Dose-related effects of prenatal 5-methoxytryptamine (5-MT) on development of serotonin terminal density and behavior (Shemer et al., 1991)
• PubMed – Effects of prenatal 5-methoxytryptamine and parachlorophenylalanine on serotonergic uptake and behavior in the neonatal rat (Shemer et al., 1988)
• PMC – Taxon- and Site-Specific Melatonin Catabolism
• Springer – Melatonin in crop plants: from biosynthesis through pleiotropic effects to enhanced stress resilience (2025)
• ScienceDirect Topics – 5-Methoxytryptamine (Overview)
• PMC – Serotonergic Modulation of Neurovascular Transmission: A Focus on Prejunctional 5-HT Receptors/Mechanisms
• PubMed – 5-Hydroxytryptamine and the gastrointestinal migrating motor complex
• American Journal of Physiology – Expression and function of 5-HT4 receptors in the mouse enteric nervous system
• Gastroenterology – Activation of Colonic Mucosal 5-HT4 Receptors Accelerates Propulsive Motility and Inhibits Visceral Hypersensitivity (2012)
• PMC – Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-MeO-DMT metabolism and pharmacokinetics
• Bentham Science – Psychedelic 5-MeO-DMT: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions
• Wikipedia – Serotonin Syndrome
• ResearchGate – R.B. Strelkov research on mexamine and radioprotection
• OSTI – Effect of high potassium and calcium ion concentrations on mexamine protection against the depilatory action of x-rays in young mice
• OSTI/ETDEWEB – Investigation of the cytogenetic activity of radioprotectors in human lymphocyte culture